Advertisement




Related Videos

Breast Cancer

Harry D. Bear, MD, PhD, on the NSABP B-51/RTOG 1304 Trial

Harry D. Bear, MD, PhD, of Massey Cancer Center, discusses abstract OT1-3-02, “Will chest wall and regional nodal radiotherapy post mastectomy or the addition of regional nodal radiotherapy to breast radiotherapy post lumpectomy reduce the rate of invasive cancer events in patients with positive axillary nodes who convert to ypN0 after neoadjuvant chemotherapy? NSABP B-51/RTOG 1304 a phase III trial.”

Breast Cancer

Jack Cuzick, PhD, on the IBIS-I Trial

Jack Cuzick, PhD, of the Wolfson Institute of Preventive Medicine, discusses abstract S3-07, "16-year long-term follow-up of the IBIS-I breast cancer prevention trial."

Breast Cancer

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, on NSABP Neoadjuvant Chemotherapy Trials

Larry Wickerham, MD, and Harry D. Bear, MD, PhD, discuss three clinical trials:

•          B-40, the only study to combine neoadjuvant and adjuvant chemotherapy with bevacizumab
•          B-51, on radiation to the chest wall
•          Alliance trial, on lymph node dissection

Breast Cancer

Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data

Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.

Breast Cancer

Clifford A. Hudis, MD, FACP, on the SOFT Trial

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.

Advertisement

Advertisement



Advertisement